Summary of the Third Quarter of 2014

  • MorphoSys and Emergent BioSolutions signed an agreement for the joint development and commercialization of MOR209/ES414, a bi-specific antibody targeting prostate cancer. Under the terms of the agreement, MorphoSys gains worldwide commercialization rights excluding the U.S. and Canada.
  • MorphoSys received a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial in the field of diabetic eye diseases.
  • In October, MorphoSys announced the acquisition of Lanthio Pharma’s lanthipeptide technology.
  • MorphoSys receives a research grant of up to EUR 1 million from the German Federal Ministry of Education and Research (BMBF), which will support development of antibodies against two G protein-coupled receptors (GPCRs).
  • Clinical data for the MOR103 program from the phase 1b study in multiple sclerosis were presented in September at the ACTRIMS-ECTRIMS meeting. The completion of the study marks the complete transition of all further development to MorphoSys’s partner GlaxoSmithKline.
  • MorphoSys provided an update on its proprietary portfolio including the clinical programs MOR208, MOR103 and MOR202. First clinical data for the MOR208 program from the phase 2 study in Non-Hodgkin’s lymphoma (NHL) will be published in Q4 2014. Results from the phase 2 study of MOR208 in acute lymphoblastic leukemia (ALL) and from the phase 1/2a study of MOR202 in multiple myeloma are expected in 2015.
  • Shortly after the end of the third quarter 2014, MorphoSys received a milestone payment from its partner Janssen Biotech for the start of a phase 3 clinical trial with guselkumab.
  • As a result of these events, MorphoSys’s partnered and proprietary pipeline currently comprises 94 therapeutic antibodies, of which 21 were in clinical development. This includes three partnered programs in phase 3 trials.


* Phase 3 was started in Oktober 2014